化疗方案比较翻译.doc

化疗方案比较翻译

泛瑞翻译
原文：
This author has personally seen responses with combinations of FolFOX (5-fluorouracil, leucovorin, and oxaliplatin), XELOX (capecitabine and oxaliplatin), and combinations with irinotecan and cetuximab. There has been some additional interesting hints of activity with combinations of capecitabine with gemcitabine, a combination initially developed for the treatment of renal cell cancer.21 Responders with capecitabine and gemcitabine more typically occur inpatients who responded to the Gem-FLP combination. Therefore, it is unlikely that this combination would overcome initial resistance to 5-fluorouracil–based therapy. Given the similarity with colonic cancer, this author would also recommend consideration of the addition of bevacizumab, and inhibitors of epidermal growth factor receptor (EGFR), including cetuximab, or panitumumab when available. This author also has seen cases in which patients may have benefited from long-term maintenance therapy with these antibodies. Additional responses have been reported with gemcitabine and cisplatin, S-1/cisplatin, and irinotecan. Unfortunately, the small numbers of patients treated limits our ability to validate these findings.

译文：
作者亲历患者接受FolFOX 化疗方案（5-氟尿嘧啶+甲酰四氢叶酸+奥沙利铂）、XELOX（卡培他滨+奥沙利铂）或伊立替康联合西妥昔单抗化疗后，出现应答。此外，卡培他滨联合吉西他滨（最早用于治疗肾细胞癌）也可能会有一定的临床获益。多数情况下，对卡培他滨联合吉西他滨产生应答的患者也对Gem-FLP化疗方案产生应答。因此，很难确定该方案能克服基于5-氟尿嘧啶的治疗方案所存在的问题。鉴于与结肠癌存在一定相似性，作者还推荐可选用贝伐单抗、表皮生长因子受体（EGFR）抑制剂，如西妥昔单抗或帕尼单抗。再者，作者亲历有些患者接受针对这些抗体的长期维持治疗后，也有一定的临床获益。其他研究表明，吉西他滨+顺铂， S-1/顺铂，与伊立替康也有一定的临床获益。但是，这些研究患者数量较少，难以判定其疗效。